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Comparison of Cardiac Troponin I
Measurements on Whole Blood and
Plasma on the Stratus CS Analyzer
and Comparison with AxSYM
To the Editor:
Assays for cardiac troponin T and
troponin I (cTnI) are powerful tools
for early identification of patients
with acute myocardial infarction
(AMI) and for pointing out subjects
at highest risk among patients with
unstable angina pectoris (1–3). These
applications require increasingly
rapid and more sensitive tests. To
this end, one of the most commonly
used automated assays for cTnI
(Stratus® II; Dade) has undergone
extensive revision (4, 5). A second-
generation quantitative radial parti-
tion immunoassay is now used in
combination with the Stratus CS flu-
orometric analyzer, a system de-
signed to meet the needs of STAT
and point-of-care testing. The Stratus
CS yields cTnI results that are clini-
cally consistent with those obtained
with the Stratus II (6 ).
The Stratus CS uses closed routine
sample tubes containing anticoagu-
lated whole blood (lithium heparin).
The system takes #14 min to centri-
fuge the tube and perform the anal-
ysis. The Stratus CS can also manage
precentrifuged plasma samples. In
the present study, the Stratus CS was
used to determine cTnI on whole
blood and on preprocessed plasma
samples drawn from the same pa-
tients. Our purpose was to check the
similarity of the results obtained for
both samples in the entire measuring
range. We also aimed at comparing
results from the Stratus CS with cTnI
results yielded by the Abbott AxSYM
analyzer, with special attention to
concentrations below the threshold
for AMI.
The Stratus CS is a fluorometric
enzyme immunoassay analyzer for
quantitative determination of the
cardiac markers creatine kinase-MB
mass, myoglobin, and cTnI (Dade
Behring). The test system uses radial
partition immunoassay technology,
which has been enhanced through
the use of a monoclonal capture an-
tibody coupled to Starburst® den-
drimers (7 ). According to the insert
for the cTnI method, coronary risk
increases at cTnI concentrations .0.4
mg/L, and this value was considered
as the cutoff for AMI in the present
study. Reference values are ,0.08
mg/L (6 ). The two monoclonal anti-
bodies used in the method recognize
both free and complexed cTnI. The
results were compared with those
obtained by the AxSYM cTnI micro-
particle enzyme immunoassay (Ab-
bott Laboratories). This system also
allows for automated quantification
of cTnI in serum or plasma (lithium
heparin) (8, 9). According to the
manufacturer’s package insert, cTnI
values .0.4 mg/L are increased
above the reference values estab-
lished in blood donors, whereas val-
ues .2.0 mg/L are indicative of AMI.
Blood samples were obtained from
85 patients hospitalized at the Uni-
versity Hospital of Lie`ge, Belgium.
Twenty-three patients were admitted
for suspected AMI; diagnosis was
confirmed in 16 cases (14 Q-wave
AMI and 2 non-Q-wave AMI), and a
myocardial lesion was excluded in 7
cases. Twelve patients had unstable
angina pectoris, 9 had stable angina,
and 19 had undergone cardiac sur-
gery. In the remaining patients were
5 patients with polytrauma, 1 non-
cardiac surgery patient, and 16
chronically hemodialyzed patients.
In this study, we used two differ-
ent types of samples: one tube (tube
I; Hemogard lithium heparin, Vacu-
tainer; Becton Dickinson) to be ana-
lyzed without further treatment on
the Stratus CS, and one (tube II;
Venoject-II lithium heparin 1 sepa-
rator; Terumo Europe) to provide the
plasma to be analyzed on the two
analyzers. A sample was collected
into tube II from each of the 85
above-mentioned patients. In a sub-
group of 53 patients, tube I was taken
in addition to tube II. Both tubes
were taken within periods of time
not exceeding 2 min. The order in
which the tubes were sampled (tube
I first or tube II first) was random-
ized in each category of patients.
Tube I was kept at room temperature
and analyzed within 2 h. No manual
treatment of the tube was required
prior to the assay.
cTnI results obtained for whole
blood were compared with the cor-
responding results obtained for
plasma aliquots from tube II, also
analyzed by the Stratus CS using the
special design for plasma samples
(comparison A1). For 15 patients, se-
lected at random among the patients
with cTnI results ,0.15 mg/L on the
Stratus CS, tube I was removed from
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the Stratus CS after completion of the
analysis, decapped, and centrifuged
manually (8000g for 10 min). The
supernatant was transferred to a cup,
kept at 4 °C, and reanalyzed on the
Stratus CS. Each plasma sample was
analyzed within 1 h after the corre-
sponding whole blood sample, and
the results were used for a second
comparison of whole blood with
plasma on the Stratus CS (compari-
son A2). Tube II was kept at room
temperature and centrifuged at
3000g within 1 h. The supernatant
was divided into two aliquots and
kept at 4 °C. One aliquot was ana-
lyzed on the Stratus CS, the other on
the AxSYM; both plasma samples
were analyzed simultaneously on the
two analyzers within 2 h after blood
collection (comparison B1). We also
compared the cTnI results obtained
on the Stratus CS (whole blood) with
those obtained on the AxSYM, using
an aliquot of plasma from tube II
(comparison B2).
The measuring range for cTnI on
the Stratus CS is 0–50 mg/L, similar
to that of the AxSYM. One sample
had to be diluted on the two instru-
ments (72.8 mg/L on Stratus CS and
369 mg/L on AxSYM). Seven addi-
tional samples (10.2–33.5 mg/L on
Stratus CS) were above the measur-
ing range on the AxSYM and had to
be diluted. The calculated results
(56.0–369.0 mg/L) were included in
the comparisons.
In the 53 patients for whom tubes I
and II were available, we compared
(comparison A1) the cTnI values ob-
tained by the Stratus CS on whole
blood and plasma; the values were
related by the equation:
Whole blood 5 (1)
0.991 ~0.981–1.01!
plasma 2 0.075
(20.20 to 0.05); r2 5 0.998
When only cTnI values ,0.15 mg/L
(n 5 29) were selected for the com-
parison, the regression equation was:
Whole blood 5 (2)
0.921 ~0.815–1.03! plasma 2 0.002
(20.008 to 0.003); r2 5 0.923
For 15 patients of the latter sub-
group, the results obtained by the
Stratus CS on whole blood were
compared with those obtained for
the plasma in the same system after
subsequent centrifugation of the
tubes (comparison A2). There was no
statistically significant difference be-
tween the initial values and results
obtained after manual centrifugation
(Student t-test for paired observa-
tions).
The comparison of measurements
obtained for plasma samples (n 5 85)
analyzed on the Stratus CS and Ax-
SYM (comparison B1) indicated that
the cTnI values on the two analyzers
were related by the equation:
Stratus CS 5 (3)
0.171 (0.166 – 0.176) AxSYM 2
0.06 (20.37 to 0.25);
r2 5 0.981
The regression equation between re-
sults obtained for whole blood on the
Stratus CS and plasma on the Ax-
SYM (comparison B2) was close to
Eq. 3. When the comparison was
performed for results obtained for
the 64 patients with cTnI values ,2.0
mg/L on the AxSYM (comparison of
plasma samples), the regression
equation was:
Stratus CS 5 (4)
0.202 (0.175– 0.229) AxSYM 1
0.015 ~0.013–0.017!; r2 5 0.789
To analyze the discrepancies be-
tween the results obtained by the
two methods in this clinically impor-
tant concentration range between the
upper reference value (URL) and the
cutoff for AMI, the cTnI results were
expressed in relation to the respec-
tive URL: results obtained on the
Stratus CS were divided by 0.08 and
those obtained on the AxSYM were
divided by 0.4. Fig. 1 shows the dis-
tribution of the differences between
each pair of transformed results (val-
ue on AxSYM minus value on Stratus
CS) in relation to their mean value.
The mean of the differences (d# ) was
not statistically different from zero,
indicating that there was no system-
atic bias toward one method. Never-
theless, based on the threshold val-
ues of the methods (0.08 and 0.4
mg/L for Stratus CS, 0.4 mg/L and
2.0 mg/L for AxSYM), nine patients
were classified in different diagnos-
tic categories according to the
method used. In four patients for
whom unstable angina or AMI was
excluded and who did not show in-
creased cardiac markers in the fol-
lowing hours or days, cTnI results on
Fig. 1. Differences between results for plasma cTnI by Stratus CS and AxSYM according to the
cTnI concentrations of the samples.
For each method, cTnI results are expressed as multiples of the URL: 0.08 mg/L for Stratus CS and 0.4 mg/L
for AxSYM. The x axis represents, for each pair of results, the mean of the transformed data; the y axis
represents the difference between the transformed data (AxSYM 2 Stratus CS). d# , mean of the differences;
sd, standard deviation of their distribution.
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AxSYM were above reference values
(0.5 and 0.6 mg/L), whereas the Stra-
tus CS yielded negative results
(,0.08 mg/L). On the other hand, in
contrast to the negative results on
AxSYM, values between 0.08 and 0.4
mg/L on the Stratus CS were found
in five samples from patients with
myocardial damage. One of these
patients was in the early phase of
AMI (the two methods indicated
positive results 2 h later), two had
unstable angina, and two others
were cardiac surgery patients (early
postoperative period). Consequently,
for all discordant results, the Stratus
CS was in agreement with the clinical
diagnosis. There was no discrepancy
between the methods for results .2.0
mg/L on the AxSYM.
In conclusion, when performed on
samples deriving from two different
tubes (whole blood and heparinized
plasma) drawn from the same pa-
tients at the same time, cTnI values
obtained by the Stratus CS in the
entire measuring range, including
values #0.15 mg/L, were statistically
indistinguishable. This attests not
only to the excellent precision of the
method, as already stated by others
(6 ), particularly in the low concentra-
tion range, but also to the quality of
the preanalytical phase automati-
cally performed by the system. The
agreement of the results allows the
system to be used on different spec-
imens in the same patients.
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Real-Time PCR Assay with
Fluorescent Hybridization Probes for
Rapid Genotyping of the CD14
Promotor Polymorphism
To the Editor:
A soluble form of CD14 (1 ) activates
endothelium and smooth muscle (2 ).
CD14 binds lipopolysaccharide, the
cell wall component of gram-nega-
tive bacteria. Upon lipopolysaccha-
ride binding, monocytes produce
pro-inflammatory cytokines and pro-
coagulant activity. In view of the
growing evidence for a role of infec-
tion with gram-negative bacteria (3 ),
inflammation, and hypercoagulabil-
ity in the onset of atherosclerosis,
two independent studies evaluated
the frequency of a genetic polymor-
phism within the promotor of the
CD14 gene in patients with myocar-
dial infarction (MI) (4, 5 ). This poly-
morphism consists of a single base
exchange (C3T) at position 2260 (4 )
[corresponding to position 2159 in
study by Unkelbach et al. (5 )], with C
introducing a HaeIII restriction site.
The polymorphic site is located
near the Sp 1 binding site of the
promotor (4 ). An increased risk for
MI in patients homozygous for the T
allele was found (4, 5). Moreover,
Unkelbach et al. (5 ) observed an
even stronger association between
the TT genotype and the risk for MI
in patients without other risk factors
such as smoking and hypertension.
The odds ratio for MI in normoten-
sive nonsmoking TT homozygotes
older than 62 years was 3.8 (5 ).
Because perioperative MI remains
a major complication in surgical pa-
tients (6 ), genotyping for the CD14
promotor polymorphism could be-
come a part of preoperative risk clas-
sification of surgical patients.
The techniques reported for CD14
genotyping (restriction fragment
length polymorphism and single-
strand conformation polymorphism
analysis) are time-consuming and re-
quire multiple manual steps. Because
a high throughput of samples is de-
sirable for future studies, we suggest
a rapid-cycle PCR with fluorescently
labeled oligonucleotide hybridiza-
tion probes on the LightCyclerTM in-
strument (Roche Diagnostics) and
subsequent fluorescent probe melt-
ing point analysis, which allows
genotyping within 60 min.
Genomic DNA samples from 100
healthy blood donors were extracted
from whole blood according to stan-
dard procedures. The reliability of
the proposed assay was confirmed
by restriction enzyme digestion with
HaeIII.
PCR was performed in disposable
capillaries (Roche Diagnostics) in a
reaction volume of 10 mL containing
1 mL of DNA (20–80 ng), 0.5 mmol/L
each of the primers (sense, 59-
GGTGCCAACAGATGAGGTTCAC-
39; antisense, 59-CTTCGGCTGCCT-
CTGACAGTT-39), 1 mL of reaction
buffer [LightCycler DNA master hy-
bridization probes 103 buffer (13 5
1.75 mmol/L); Roche Diagnostics],
and 0.2 mmol/L each of the probes.
The detection probe specific for the T
allele (59-TTCCTGTTACGGCCCC-
CCT-39) was labeled at the 39 end
with fluorescein. The anchor probe
(59-GGAGACACAGAACCCTAGAT-
GCCCTGCA-39) was labeled with
LightCycler Red 640 at the 59 end
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